proagio
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 29, 2021 (NCT05085548)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Caspase-8ACTIVATOR
CASP8 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06867822 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | University of Alabama, Birmingham, V Foundation |
| NCT06460298 | Phase 1/Phase 2 (Phase 2) | Aug 20, 2024 | Emory University, Georgia State University, ProDa BioTech, LLC |
| NCT06182072 | Phase 1 | Dec 29, 2023 | Georgia State University, ProDa BioTech, LLC, University of Alabama, Birmingham |
| NCT05085548 | Phase 1 | Oct 29, 2021 | National Cancer Institute (NCI), ProDa BioTech, LLC |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ProDa BioTech, LLC | For profit | 3 | 3 | 2 | 2021 |
| Georgia State University | Academic/Hospital | 2 | 0 | 2 | 2023 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 1 | 2 | 2023 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| V Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
6 organizations
Page 1 / 1